What Aldara™ Cream is used for
Aldara™ Cream has been approved for the treatment of three common skin diseases:
Actinic Keratosis: In two double-blind, vehicle-controlled clinical studies, 436 patients with actinic keratosis (AK) were treated with Aldara™ Cream or vehicle cream 2 times per week for 16 weeks. Patients with 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or scalp were enrolled and randomized to active or vehicle treatment. The population studied ranged from 37-88 years of age (median 66 years) and 55% had Fitzpatrick skin type I or II. All imiquimod-treated patients were Caucasians. The primary efficacy variable was the complete clearance rate. Complete clearance included clearance of all baseline lesions, as well as any new or subclinical AK lesions which appeared during therapy.
Superficial Basal Cell Carcinoma: In two double-blind, vehicle-controlled clinical studies, 364 patients with primary superficial basal cell carcinoma (sBCC) were treated with Aldara™ Cream or vehicle cream 5X/week for 6 weeks. The primary efficacy variable was the complete response rate defined as the proportion of patients with clinical (visual) and histological clearance of the sBCC lesion at 12 weeks post-treatment.
External Genital Warts: In a double-blind, placebo-controlled clinical study, 209 otherwise healthy patients 18 years of age and older with genital/perianal warts were treated with Aldara™ Cream or vehicle control 3X/week for a maximum of 16 weeks. The median baseline wart area was 69 mm2. The median time to complete wart clearance was 10 weeks.